Sulfur Amino Acid Metabolism: Transsulfuration and One-Carbon
Sulfur amino acids (SAAs; Met and Cys; essential/conditionally essential; Met: essential (SAM cycle entry); Cys: conditionally essential (Met → Cys via transsulfuration); important for: GSH, taurine, CoA, methylation, H2S production): methionine cycle (Met → SAM (S-adenosylmethionine; universal methyl donor; MAT1A/MAT2A) → SAH (S-adenosylhomocysteine; product inhibitor; SAHH → Hcy (homocysteine)); Hcy (branching point): (1) remethylation (MTHFR/B12/folate → Met; BHMT (betaine) → Met); (2) transsulfuration (CBS (cystathionine β-synthase; PLP/B6; Hcy + Ser → cystathionine) → CSE (cystathionase; PLP/B6; cystathionine → Cys + α-ketobutyrate); produces Cys for: GSH γ-GCS/GSS pathway; taurine (CDO1: Cys dioxygenase → cysteine sulphinate → CSAD decarboxylase → hypotaurine → taurine); CoA (pantothenate + Cys); protein synthesis)); H2S (hydrogen sulphide; gasotransmitter; produced by: CBS (Hcy + Cys → H2S), CSE (Cys → H2S + pyruvate + NH3), 3-MST/CAT; H2S signalling: Kv channels (S-sulfhydration Cys → vasodilation); Complex IV mild inhibition (similar to CO; low nM anti-inflammatory; high µM toxic); NF-κB S-sulfhydration p65 Cys38 → anti-inflammatory; HIF-1α PHD2 S-sulfhydration → HIF-1α stabilisation).
Spirulina Mechanisms in Sulfur Amino Acid Metabolism
Methionine/Cysteine Substrate Provision
Spirulina protein (60–70% dry weight; complete amino acid profile; SAA content: methionine ~1.3 g/100g protein; cysteine ~0.7 g/100g protein; combined SAA ~2 g/100g protein; digestibility-corrected PDCAAS: 0.9–1.0 for spirulina vs. 1.0 for casein/egg; SAA limiting factor in some plant proteins but adequate in spirulina) provides: (1) Met as SAM cycle substrate (Met → SAM → methylation of DNA/histone/phosphatidylethanolamine/creatine/carnitine → Hcy → transsulfuration Cys; 5g spirulina provides ~65 mg Met); (2) Cys directly (5g spirulina ~35 mg Cys; reduces transsulfuration demand; Cys is rate-limiting for γ-GCS (glutamate-cysteine ligase; Km Cys ~0.3 mM) in GSH synthesis; direct Cys supplementation → GSH +10–20% in Cys-limited conditions); (3) B6 (pyridoxal phosphate; spirulina 0.3–0.4 mg/100g; CBS/CSE PLP cofactor → transsulfuration efficiency; B6 deficiency → homocysteine elevation (CBS/CSE impaired)); (4) Folate (spirulina ~94 µg/100g; MTHFR cofactor → MTHF → Hcy remethylation → reduced Hcy → less Hcy toxicity, more Hcy flux to Cys via transsulfuration). Net: SAM cycle flux + transsulfuration Cys production supported; homocysteine −5–10% (folate/B6 effect) in supplementation studies.
γ-GCS/GSS Glutathione Synthesis: Cysteine Rate-Limiting Step
GSH synthesis (two-enzyme pathway; γ-GCS (glutamate-cysteine ligase; GCL; heterodimer: GCLc (catalytic) + GCLm (modifier); rate-limiting; Km Cys ~0.3 mM; Km Glu ~1.8 mM; Km ATP ~0.1 mM; inhibited by GSH product feedback; induced by Nrf2/ARE (GCLc/GCLm ARE sites)); GSS (glutathione synthetase; GSH precursor: γ-GluCys + Gly + ATP → GSH; usually not rate-limiting)) depends on Cys availability. Spirulina supports GSH synthesis via two parallel mechanisms: (1) Cys substrate (direct provision + transsulfuration CBS/CSE/B6 → Cys pool elevation; GSH +15–30% in erythrocyte/hepatocyte models); (2) Nrf2-GCLc/GCLm induction (phycocyanobilin Keap1-Cys modification → Nrf2 → GCLc +25–40%, GCLm +20–35% → increased GSH synthetic capacity independent of substrate; Nrf2 also induces: GPx1/2 (GSH utilisation for H2O2 reduction; balanced with GSH production); GR (glutathione reductase; GSSG → GSH → recycling; NADPH-dependent; Nrf2 target)). Net: GSH +15–30% in oxidatively stressed cells; GSSG/GSH ratio −20–40% (more reduced redox state).
Taurine Provision: Bile Acid Conjugation and Osmoprotection
Taurine (2-aminoethanesulphonic acid; conditionally essential; Cys → CSA (cysteine sulphinate; CDO1 Fe2+-dependent dioxygenase) → hypotaurine (CSAD; PLP/B6) → taurine (spontaneous oxidation); functions: (1) bile acid conjugation (BAAT: bile acid CoA:amino acid N-acyltransferase → taurocholate/taurochenodeoxycholate; taurine-conjugated bile acids: higher solubility, lower pKa (2.0 vs. 4.5 for glycine-conjugates → ionised at intestinal pH → better micelle formation → fat-soluble vitamin absorption)); (2) osmotic cell volume regulation (skeletal muscle, heart, liver → taurine transporter TauT: Na+-dependent; intracellular taurine 20–60 mM in cardiomyocytes; hyperosmolarity → TauT upregulation → taurine accumulation → osmotic equilibrium); (3) mitochondrial tRNALys modification (5-taurinomethyluridine; mt-tRNA modification by taurine → mitochondrial protein synthesis fidelity; taurine deficiency → mitochondriopathy MERRF-like); (4) Ca2+ modulation in heart (taurine → Na+/Ca2+ exchanger → reduced intracellular Ca2+ overload; anti-arrhythmic); (5) GABA-A receptor modulation (taurine: inhibitory neurotransmitter-like; GABA-A agonist at µM concentrations in brainstem/neonatal brain)). Spirulina taurine: 1.5–2.5 mg/g (~75–125 mg at 5g dose); contributes to taurine pool; CDO1 Cys provision for de novo taurine synthesis also supported.
H2S Gasotransmitter and Vascular Signalling
H2S (hydrogen sulphide; gasotransmitter; endogenous vascular/neural signal; produced by CBS/CSE/3-MST; plasma H2S: 10–300 nM (species/method-dependent); tissue H2S: µM; signalling mechanisms: (1) Kv channel S-sulfhydration (persulfidation at Cys residues; Kv1.5 Cys → channel opening → K+ efflux → membrane hyperpolarisation → Ca2+ entry reduction → vascular smooth muscle relaxation → vasodilation); (2) NF-κB p65 Cys38 persulfidation (S-sulfhydration → p65 nuclear localisation inhibition → anti-inflammatory; distinct from NO/S-nitrosylation which also inhibits p65 Cys38); (3) Complex IV S-sulfhydration (CuA/CuB-adjacent Cys in COX2; low-dose H2S → mild ETC inhibition → AMPK; high-dose → toxic); (4) KATP channel (H2S → S-sulfhydration Kir6.1 Cys → channel opening → cytoprotection in ischaemia/reperfusion); (5) Nrf2 Keap1-Cys persulfidation (H2S → Keap1 Cys151/288 persulfide → Nrf2 release → HO-1/NQO1 → antioxidant amplification)). Spirulina: (1) CBS/CSE B6 cofactor provision (PLP from B6 → optimal CBS/CSE activity → H2S synthesis); (2) Cys substrate provision → CSE → H2S; (3) NO (eNOS → NO) + H2S cross-talk: H2S + NO → nitroxyl (HNO) + thionitrous acid → KATP activation → vasoprotection. H2S +10–20% in B6-replete spirulina conditions.
Clinical Outcomes in Sulfur Amino Acid Metabolism
- GSH (erythrocyte/plasma; 8–12 weeks): +15–30%
- GSSG/GSH ratio (redox status): −20–40%
- Homocysteine (plasma; folate/B6 effect): −5–10%
- Taurine (plasma/urinary; CDO1/Cys provision): +10–20%
- GCLc/GCLm mRNA (Nrf2-driven): +25–40%
- 8-isoprostane (GSH/taurine antioxidant effect): −15–25%
Dosing and Drug Interactions
Oxidative stress/GSH support: 5–10g daily with B6-containing diet for 8–16 weeks. NAC (N-acetylcysteine; Cys donor): NAC + spirulina: complementary Cys provision for GSH synthesis; additive GSH elevation. Methionine restriction (longevity; IGF-1 axis): Spirulina Met provision (~65 mg/5g) is modest; unlikely to significantly antagonise Met restriction protocols; taurine/H2S benefits preserved. Taurine supplements: Spirulina taurine (75–125 mg/5g) + supplemental taurine (500–2000 mg): additive; no ceiling toxicity for taurine. Isoniazid (B6 antagonist; TB): INH depletes PLP → impairs CBS/CSE → Hcy elevation; spirulina B6 provision may partially mitigate INH-B6 depletion; monitor Hcy in TB patients on INH + spirulina. Methotrexate (antifolate): MTX depletes folate → MTHFR inhibition → Hcy elevation; spirulina folate provision (94 µg/100g) may partially offset MTX-related Hcy elevation. Summary: GSH +15–30%, Hcy −5–10%, taurine +10–20%, GCLc +25–40%; dosing 5–10g daily. NK concern: low.